Abstract：
UNASSIGNED: One major challenge in developing personalised repetitive transcranial magnetic stimulation (rTMS) is that the treatment responses exhibited high inter-individual variations. Brain morphometry might contribute to these variations. This study sought to determine whether individual\'s brain morphometry could predict the rTMS responders and remitters.
UNASSIGNED: This was a secondary analysis of data from a randomised clinical trial that included fifty-five patients over the age of 60 with both comorbid depression and neurocognitive disorder. Based on magnetic resonance imaging scans, estimated brain age was calculated with morphometric features using a support vector machine. Brain-predicted age difference (brain-PAD) was computed as the difference between brain age and chronological age.
UNASSIGNED: The rTMS responders and remitters had younger brain age. Every additional year of brain-PAD decreased the odds of relieving depressive symptoms by ∼25.7% in responders (Odd ratio [OR] = 0.743, p = .045) and by ∼39.5% in remitters (OR = 0.605, p = .022) in active rTMS group. Using brain-PAD score as a feature, responder-nonresponder classification accuracies of 85% (3rd week) and 84% (12th week), respectively were achieved.
UNASSIGNED: In elderly patients, younger brain age appears to be associated with better treatment responses to active rTMS. Pre-treatment brain age models informed by morphometry might be used as an indicator to stratify suitable patients for rTMS treatment.
UNASSIGNED: ClinicalTrials.gov Identifier: ChiCTR-IOR-16008191.
UNASSIGNED: This was a secondary analysis of data from a randomised clinical trial that included fifty-five patients over the age of 60 with both comorbid depression and neurocognitive disorder. Based on magnetic resonance imaging scans, estimated brain age was calculated with morphometric features using a support vector machine. Brain-predicted age difference (brain-PAD) was computed as the difference between brain age and chronological age.
UNASSIGNED: The rTMS responders and remitters had younger brain age. Every additional year of brain-PAD decreased the odds of relieving depressive symptoms by ∼25.7% in responders (Odd ratio [OR] = 0.743, p = .045) and by ∼39.5% in remitters (OR = 0.605, p = .022) in active rTMS group. Using brain-PAD score as a feature, responder-nonresponder classification accuracies of 85% (3rd week) and 84% (12th week), respectively were achieved.
UNASSIGNED: In elderly patients, younger brain age appears to be associated with better treatment responses to active rTMS. Pre-treatment brain age models informed by morphometry might be used as an indicator to stratify suitable patients for rTMS treatment.
UNASSIGNED: ClinicalTrials.gov Identifier: ChiCTR-IOR-16008191.
摘要：
开发个性化重复经颅磁刺激（rTMS）的一个主要挑战是治疗反应表现出高的个体间差异。大脑形态测量可能会导致这些变化。这项研究试图确定个体的大脑形态测量是否可以预测rTMS反应者和缓解者。
这是对一项随机临床试验数据的二次分析，该试验包括55名60岁以上患有抑郁症和神经认知障碍的患者。根据磁共振成像扫描，估计的大脑年龄是使用支持向量机计算的形态特征。大脑预测的年龄差异（brain-PAD）计算为大脑年龄和实际年龄之间的差异。
■rTMS反应者和汇款者的大脑年龄较小。在活跃的rTMS组中，大脑PAD每增加一年，缓解抑郁症状的几率降低~25.7%（奇数比[OR]=0.743，p=0.045），缓解者降低~39.5%（OR=0.605，p=.022）。使用大脑PAD得分作为特征，应答者-无应答者分类准确率为85%(第3周)和84%(第12周)，分别实现了。
■在老年患者中，较年轻的大脑年龄似乎与对活动性rTMS的更好治疗反应相关。由形态计量学告知的治疗前脑年龄模型可以用作对rTMS治疗的合适患者进行分层的指标。
■ClinicalTrials.gov标识符：ChiCTR-IOR-16008191。
这是对一项随机临床试验数据的二次分析，该试验包括55名60岁以上患有抑郁症和神经认知障碍的患者。根据磁共振成像扫描，估计的大脑年龄是使用支持向量机计算的形态特征。大脑预测的年龄差异（brain-PAD）计算为大脑年龄和实际年龄之间的差异。
■rTMS反应者和汇款者的大脑年龄较小。在活跃的rTMS组中，大脑PAD每增加一年，缓解抑郁症状的几率降低~25.7%（奇数比[OR]=0.743，p=0.045），缓解者降低~39.5%（OR=0.605，p=.022）。使用大脑PAD得分作为特征，应答者-无应答者分类准确率为85%(第3周)和84%(第12周)，分别实现了。
■在老年患者中，较年轻的大脑年龄似乎与对活动性rTMS的更好治疗反应相关。由形态计量学告知的治疗前脑年龄模型可以用作对rTMS治疗的合适患者进行分层的指标。
■ClinicalTrials.gov标识符：ChiCTR-IOR-16008191。
